Chris Collins , vice president and director of public policy for the American Foundation for AIDS Research , said the data on the drug ' s prophylactic use were compelling and urged the committee not to limit access to it . " We need new tools to fight this epidemic that include treatment , condoms and education , " Collins said . " PrEP is certainly not for everyone , but it may have a role in bringing HIV infection rates down . It ' s time to learn how PrEP may be useful in the real world . "
